Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue – Cohort Study

English version České info

Background:
Transparency in reporting of conflict of interest is an increasingly important aspect of publication in medical journals. Publication of large industry-supported trials may generate many citations and journal income through reprint sales and thereby be a source of conflicts of interest for journals. We investigated industry-supported trials' influence on journal impact factors and revenue.

Methods and Findings:
We sampled six major medical journals (Annals of Internal Medicine, Archives of Internal Medicine, BMJ, JAMA, The Lancet, and New England Journal of Medicine [NEJM]). For each journal, we identified randomised trials published in 1996–1997 and 2005–2006 using PubMed, and categorized the type of financial support. Using Web of Science, we investigated citations of industry-supported trials and the influence on journal impact factors over a ten-year period. We contacted journal editors and retrieved tax information on income from industry sources. The proportion of trials with sole industry support varied between journals, from 7% in BMJ to 32% in NEJM in 2005–2006. Industry-supported trials were more frequently cited than trials with other types of support, and omitting them from the impact factor calculation decreased journal impact factors. The decrease varied considerably between journals, with 1% for BMJ to 15% for NEJM in 2007. For the two journals disclosing data, income from the sales of reprints contributed to 3% and 41% of the total income for BMJ and The Lancet in 2005–2006.

Conclusions:
Publication of industry-supported trials was associated with an increase in journal impact factors. Sales of reprints may provide a substantial income. We suggest that journals disclose financial information in the same way that they require them from their authors, so that readers can assess the potential effect of different types of papers on journals' revenue and impact.

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue – Cohort Study. PLoS Med 7(10): e32767. doi:10.1371/journal.pmed.1000354
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000354

Souhrn

Zdroje

1. International Committee of Medical Journal Editors 2010 Uniform requirements for manuscripts submitted to biomedical journals: ethical considerations in the conduct and reporting of research: conflicts of interest. April 2010. Available: http://www.icmje.org/urm_full.pdf. Accessed 30 August 2010

2. GuyattGH

NaylorD

RichardsonWS

GreenL

HaynesRB

2000 What is the best evidence for making clinical decisions? JAMA 284 3127 3128

3. SmithR

2005 Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med 2 e138 doi:10.1371/journal.pmed.0020138

4. SmithR

2006 Lapses at the New England journal of medicine. J R Soc Med 99 380 382

5. HaivasI

SchroterS

WaechterF

SmithR

2004 Editors' declaration of their own conflicts of interest. CMAJ 171 475 476

6. GarfieldE

2006 The history and meaning of the journal impact factor. JAMA 295 90 93

7. Thomson Reuters ISI Web of Knowledge. Web of Science. Available: http://www.isiknowledge.com. Accessed 11 March 2010

8. Thomson Reuters ISI Web of Knowledge. Journal Citation Reports. Available: http://www.isiknowledge.com. Accessed 11 March 2010

9. FlanaginA

CareyLA

FontanarosaPB

PhillipsSG

PaceBP

1998 Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA 280 222 224

10. McVeighME

MannSJ

2009 The journal impact factor denominator: defining citable (counted) items. JAMA 302 1107 1109 Erratum in: (2009) JAMA 302: 1972

11. MoedHF

van LeeuwenTN

1996 Impact factors can mislead. Nature 381 186

12. KulkarniAV

BusseJW

ShamsI

2007 Characteristics associated with citation rate of the medical literature. PLoS ONE 2 e403 doi:10.1371/journal.pone.0000403

13. ConenD

TorresJ

RidkerPM

2008 Differential citation rates of major cardiovascular clinical trials according to source of funding: a survey from 2000 to 2005. Circulation 118 1321 1327

14. LexchinJ

BeroLA

DjulbegovicB

ClarkO

2003 Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326 1167 1170

15. BoutronI

DuttonS

RavaudP

AltmanDG

2010 Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 303 2058 2064

16. RossJS

HillKP

EgilmanDS

KrumholzHM

2008 Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 299 1800 1802

17. SteinmanMA

BeroLA

ChrenM

LandefeldCS

2006 Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med 145 284 293

18. HealyD

CattellD

2003 Interface between authorship, industry and science in the domain of therapeutics. Br J Psychiatry 183 22 27

19. PLoS Medicine Editors 2009 Ghostwriting: the dirty little secret of medical publishing that just got bigger. PLoS Med 6 e1000156 doi:10.1371/journal.pmed.1000156

20. HopewellS

ClarkeM

2003 How important is the size of a reprint order? Int J Technol Assess Health Care 19 711 714

21. SmithR

2003 Medical journals and pharmaceutical companies: uneasy bedfellows. BMJ 326 1202 1205

22. PhillipsDP

KanterEJ

BednarczykB

TastadPL

1991 Importance of the lay press in the transmission of medical knowledge to the scientific community. N Engl J Med 325 1180 1183

23. SmithR

2006 Commentary: the power of the unrelenting impact factor–is it a force for good or harm? Int J Epidemiol 35 1129 1130

24. BMJ Group Reprints service 2010. Available: http://group.bmj.com/group/advertising/mediapack/BMJ%20Reprints_2010_row_final.pdf. Accessed 11 March 2010

25. New England Journal of Medicine Article reprints from the New England Journal of Medicine. Available: http://www.nejmadsales.org/downloads/Reprints_promotional_slim-jim_05.pdf. Accessed 11 March 2010

26. House of Commons Health Committee 2005 The influence of the pharmaceutical industry. Fourth report of session 2004–2005, Volume II. March 2005. Available: http://www.parliament.the-stationery-office.co.uk/pa/cm200405/cmselect/cmhealth/42/42ii.pdf. Accessed 11 March 2010

27. GlassmanPA

Hunter-HayesJ

NakamuraT

1999 Pharmaceutical advertising revenue and physician organizations: how much is too much? West J Med 171 234 238

28. WilkesMS

DoblinBH

ShapiroMF

1992 Pharmaceutical advertisements in leading medical journals: experts' assessments. Ann Intern Med 116 912 919

29. LexchinJ

LightDW

2006 Commercial influence and the content of medical journals. BMJ 332 1444 1447

30. Elsevier Pharma Solutions Your partner for an effective communication strategy. Available: http://www.elsevier.ru/attachments/editor/files/mod_structure_220/elsevier_pharma_solutions.pdf. Accessed 11 March 2010

31. International Committee of Medical Journal Editors 2010 ICMJE uniform disclosure form for potential conflicts of interest. July 2010. Available: http://www.icmje.org/coi_disclosure.pdf. Accessed 31 August 2010